FY2026 EPS Estimates for Creative Medical Technology Holdings, Inc. Decreased by Analyst (NASDAQ:CELZ)

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) – Stock analysts at Roth Capital reduced their FY2026 earnings per share (EPS) estimates for shares of Creative Medical Technology in a report issued on Monday, May 13th. Roth Capital analyst J. Aschoff now forecasts that the company will earn $2.23 per share for the year, down from their prior forecast of $2.42. The consensus estimate for Creative Medical Technology’s current full-year earnings is ($4.68) per share. Roth Capital also issued estimates for Creative Medical Technology’s FY2027 earnings at $5.34 EPS and FY2028 earnings at $6.99 EPS.

Creative Medical Technology (NASDAQ:CELZ) last issued its earnings results on Friday, March 22nd. The company reported ($1.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.13) by ($0.08).

Creative Medical Technology Price Performance

NASDAQ:CELZ opened at $4.32 on Tuesday. Creative Medical Technology has a one year low of $3.93 and a one year high of $10.28. The firm has a 50-day moving average of $5.10 and a 200-day moving average of $4.65.

Hedge Funds Weigh In On Creative Medical Technology

A hedge fund recently bought a new stake in Creative Medical Technology stock. Aaron Wealth Advisors LLC bought a new position in shares of Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 16,400 shares of the company’s stock, valued at approximately $85,000. Aaron Wealth Advisors LLC owned 1.21% of Creative Medical Technology as of its most recent SEC filing. Hedge funds and other institutional investors own 1.42% of the company’s stock.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc, a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease.